RhumbLine Advisers
IMMX icon

RhumbLine Advisers’s Immix Biopharma IMMX Stock Holding History

RhumbLine Advisers’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$678K Buy
65,127
+14,183
+28% +$161K ﹤0.01% 2531
2026
Q2 		$525K Buy
+50,944
New +$473K ﹤0.01% 2736

Other funds holding IMMX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Monashee Investment Management
Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return
Institute for Wealth Management
Institute for Wealth Management Denver, Colorado $1.13B AUM 31.46% 1-Year Est. Return
Picton Mahoney Asset Management
Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

RhumbLine Advisers's IMMX Position: Q3 2026 in Review

RhumbLine Advisers increased its Immix Biopharma (IMMX) stake by 28% in Q3 2026, buying an estimated $161K and bringing the position to 65,127 shares worth $678K. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

RhumbLine Advisers first reported a position in IMMX in Q2 2026 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold IMMX as of Q3 2026.

  • RhumbLine Advisers held 65,127 shares of Immix Biopharma worth $678K as of Q3 2026.
  • RhumbLine Advisers bought 14,183 Immix Biopharma shares in Q3 2026, an estimated $161K.
  • Immix Biopharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2531 holding.
  • RhumbLine Advisers first reported a position in Immix Biopharma in Q2 2026 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held Immix Biopharma as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.